|
1
|
Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.
|
N Engl J Med
|
1996
|
2.86
|
|
2
|
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.
|
Cancer J Sci Am
|
2000
|
2.06
|
|
3
|
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
|
J Clin Oncol
|
2001
|
1.58
|
|
4
|
A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection.
|
J Infect Dis
|
1999
|
1.26
|
|
5
|
High-dose aldesleukin in renal cell carcinoma: long-term survival update.
|
Cancer J Sci Am
|
1997
|
1.15
|
|
6
|
Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group.
|
J Infect Dis
|
1998
|
1.09
|
|
7
|
Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons.
|
J Infect Dis
|
1997
|
1.08
|
|
8
|
Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity.
|
Blood
|
1995
|
0.98
|
|
9
|
Effects of cytochalasins B and D on alloxan inhibition of insulin release.
|
Biochem Biophys Res Commun
|
1975
|
0.97
|
|
10
|
Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.
|
Blood
|
1999
|
0.92
|
|
11
|
Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinoma.
|
Invest New Drugs
|
1994
|
0.82
|
|
12
|
Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors.
|
Cancer
|
1993
|
0.81
|
|
13
|
Recombinant human thrombopoietin clinical development.
|
Stem Cells
|
1998
|
0.77
|
|
14
|
Phase II trial of recombinant human macrophage colony-stimulating factor in metastatic soft tissue sarcoma.
|
J Immunother Emphasis Tumor Immunol
|
1994
|
0.75
|
|
15
|
Diagnosis of Cholera.
|
Prov Med J Retrosp Med Sci
|
1842
|
0.75
|